FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2443-2447 December 2, 2004 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Vaccines have eradicated smallpox, eliminated major outbreaks of diseases, and prevented thousands of deaths annually. This success can be attributed to a private vaccine industry that has produced many important new vaccines and to an aggressive public health program that annually immunizes more than three quarters of children and more than half of all adults in the United States.^1,2 The successes are now threatened by systemic problems in the development, purchase, and distribution of vaccines.

The Vaccine-Supply Industry

The number of companies that produce vaccines for the United States has declined markedly since the 1960s. Today only five companies produce all routine vaccines . . . [Full Text of this Article]

Why So Few Vaccine Suppliers?

Immunization Coverage

What Can Be Done?

The Institute of Medicine Report

How the Subsidy Would Work

Practical and Political Challenges

Source Information

From the Department of Economics, Duke University, Durham, N.C. (F.A.S.); the Children's Outcomes Research Program, University of Colorado School of Medicine, and Children's Hospital, Denver (S.B.); and the Department of Health Policy, George Washington University Medical Center (S.R.), and the Division of Behavioral and Social Sciences and Education and the Institute of Medicine, the National Academies (R.A.C., R.B.G.) — both in Washington, D.C.

Related Letters:

The U.S. Vaccine Supply
Hinman A. R., Schwartz H. K., Sloan F. A., Chalk R. A., Giffin R. B.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:1046-1047, Mar 10, 2005. Correspondence

This article has been cited by other articles:

• Weiss, M. M., Weiss, P. D., Weiss, J. B. (2007). Anthrax Vaccine and Public Health Policy. Am. J. Public Health 97: 1945-1951 [Abstract] [Full Text]  
• Szilagyi, P. G., Griffin, M. R., Shone, L. P., Barth, R., Zhu, Y., Schaffer, S., Ambrose, S., Roy, J., Poehling, K. A., Edwards, K. M., Walker, F. J., Schwartz, B., for the New Vaccine Surveillance Network, (2006). The Impact of Conjugate Pneumococcal Vaccination on Routine Childhood Vaccination and Primary Care Use in 2 Counties. Pediatrics 118: 1394-1402 [Abstract] [Full Text]  
• Mello, M. M., Brennan, T. A. (2005). Legal Concerns and the Influenza Vaccine Shortage. JAMA 294: 1817-1820 [Full Text]  
• Hinman, A. R., Schwartz, H. K., Sloan, F. A., Chalk, R. A., Giffin, R. B. (2005). The U.S. Vaccine Supply. NEJM 352: 1046-1047 [Full Text]